In a number of human melanoma model experiments, using SCID mice and the A375 human melanoma cell line, the company demonstrated that vitiligo-derived IgG preparations can prevent, in a statistically significant manner, the growth of subcutaneous melanomas (tumors). In these experiments, IgG preparations derived from vitiligo donors were compared to a variety of other IgG preparations and also compared to saline.
Steven Katz, chairman of the board and president of GammaCan, said: “Our data are highly encouraging in that they demonstrate, for the first time, in human melanoma models, anti-melanoma activity from IgG preparations derived from vitiligo donors. These positive results keep us on track to file our IND with the FDA in the near term.”